Jon Kaeuper to join later in June as VP-marketing responsible for the marketing organization of the former Lyphomed ethical drug and Fujisawa/SmithKline units, which were combined in April ("The Pink Sheet" April 9, T&G-7). Kaeuper joins from SmithKline Beecham, where he was VP-Anti-infective/Cardiovascular Product Group-U.S. Cynthia Yost of Lyphomed reports to Kaeuper as the new director of marketing. She joined Lyphomed two years ago from Bristol-Myers.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.